Galapagos sees another program spurned by big pharma
This article was originally published in Scrip
Executive Summary
Galapagos says its alliance with Janssen Pharmaceutica is "still very much alive" despite news that the Belgian biotech is regaining full rights to a G-coupled protein receptor 84 (GPR84) program from the J&J company.